JPRN-UMIN000028986已完成未知
The effect of rifaximin on small intestinal motility and microbiota in patients with liver cirrhosis - The changes of small intestinal motility and microbiota after the use of rifaximin
Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University0 个研究点目标入组 20 人开始时间: 2017年9月5日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Others,meta-analysis etc
入排标准
- 年龄范围
- 20years-old 至 99years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. The patient who is pregnant or performing breast feeding. 2. The patient who was registered in this study before. 3. The patient who has allergy to rifaximin. 4. The patient who has colostomy or cannot collect stool correctly. 5. The patient who has severe constipation and a risk for ileus by preparation for cine-MRI. 6. The patient who has contraindications for MRI (i.e. a cardiac pace maker, claustrophobia, metal product in the body, etc.). 7. The patients who are judged by the investigators to be inappropriate participants in the trial.
研究者
相似试验
已完成
2 期
Rifaximin as a Modulator of Microbial Translocation and Immune ActivationHIV-1 InfectionNCT01466595Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections73
进行中（未招募）
不适用
Intestinal decontamination with rifaximiiver cirrhosis of any etilogy, complicated by decompensation and classified as Child-Pugh B or CMedDRA version: 17.1Level: LLTClassification code 10024667Term: Liver cirrhosisSystem Organ Class: 100000004871EUCTR2012-002890-71-DKFlemming Bendtsen
已完成
4 期
Intestinal Decontamination With Rifaximin. The Inflammatory and Circulatory State in Patients With CirrhosisAscitesLiver CirrhosisNCT01769040Copenhagen University Hospital, Hvidovre54
尚未招募
不适用
Gut decontamination by rifaximin in patients with predicted severe acute pancreatitisCTRI/2021/11/037721Department of gastroenterology and heaptology
已完成
4 期
Rifaximin Therapy in Chronic Kidney DiseaseChronic Kidney DiseaseNCT02342639Jason Stubbs, MD38